Credelio

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

lotilaner

Available from:

Elanco GmbH

ATC code:

QP53BE04

INN (International Name):

lotilaner

Therapeutic group:

Dogs; Cats

Therapeutic area:

Ektoparasitaċidali għall-użu sistemiku, Isoxazolines

Therapeutic indications:

Għat-trattament tal-briegħed u l-qurdien infestazzjonijiet. Il-briegħed u l-qurdien għandhom jingħaqdu ma 'l-ospitant u jibdew jgħumu sabiex ikunu esposti għas-sustanza attiva. Il-prodott mediċinali veterinarju jista 'jintuża bħala parti minn strateġija tat-trattament għall-kontroll ta' dermatite allerġika tal-bergħud (FAD). DogsThis-prodott mediċinali veterinarju jipprovdi immedjata u persistenti joqtol l-attività għal xahar 1 għall-briegħed (Ctenocephalides felis u C. canis) u l-qurdien (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus u Dermacentor reticulatus). CatsThis-prodott mediċinali veterinarju jipprovdi immedjata u persistenti joqtol l-attività għal xahar 1 kontra l-briegħed (Ctenocephalides felis u C. canis) u l-qurdien (Ixodes ricinus).

Product summary:

Revision: 5

Authorization status:

Awtorizzat

Authorization date:

2017-04-23

Patient Information leaflet

                                23
B. FULJETT TA’ TAGHRIF
24
FULJETT TA’ TAGĦRIF GĦAL:
CREDELIO 56 MG PILLOLI LI JINTMAGĦDU GĦALL-KLIEB (1.3–2.5 KG)
CREDELIO 112 MG PILLOLI LI JINTMAGĦDU GĦALL-KLIEB (>2.5–5.5 KG)
CREDELIO 225 MG PILLOLI LI JINTMAGĦDU GĦALL-KLIEB (>5.5–11 KG)
CREDELIO 450 MG PILLOLI LI JINTMAGĦDU GĦALL-KLIEB (>11–22 KG)
CREDELIO 900 MG PILLOLI LI JINTMAGĦDU GĦALL-KLIEB (>22–45 KG)
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Il-Ġermanja
Manifattur responsabbli għall-ħruġ tal-lott:
Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, Franza
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Credelio 56 mg pilloli li jintmagħdu għall-klieb (1.3–2.5 kg)
Credelio 112 mg pilloli li jintmagħdu għall-klieb (>2.5–5.5 kg)
Credelio 225 mg pilloli li jintmagħdu għall-klieb (>5.5–11 kg)
Credelio 450 mg pilloli li jintmagħdu għall-klieb (>11–22 kg)
Credelio 900 mg pilloli li jintmagħdu għall-klieb (>22–45 kg)
lotilaner
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull pillola li tintmagħad fiha:
CREDELIO PILLOLI LI JINTMAGĦDU GĦAL KLIEB
LOTILANER (MG)
għall-klieb (1.3–2.5 kg)
56.25
għall-klieb (>2.5–5.5 kg)
112.5
għall-klieb (>5.5–11 kg)
225
għall-klieb (>11–22 kg)
450
għall-klieb (>22–45 kg)
900
Pilloli li jintmagħdu, tondi, ta’ lewn abjad sa kannella ċar,
b’tikek jagħtu fil-kannella.
4.
INDIKAZZJONI(JIET)
Kura ta’ infestazzjonijiet tal-briegħed u tal-qurdien fil-klieb.
Dan il-prodott mediċinali veterinarju jipprovdi attività immedjata u
persistenti ta’ qtil għal xahar, għal
briegħed (
_Ctenocephalides felis _
u
_C. canis_
) u qurdien (
_Rhipicephalus sanguineus, Ixodes ricinus, _
_I. hexagonus, u Dermacentor reticulatus_
).
Il-briegħed u l-qurdien iridu jeħlu mal-kelb (l-ospitu) u jibdew
jie
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Credelio 56 mg pilloli li jintmagħdu għall-klieb (1.3-–2.5 kg)
Credelio 112 mg pilloli li jintmagħdu għall-klieb (>2.5–5.5 kg)
Credelio 225 mg pilloli li jintmagħdu għall-klieb (>5.5–11 kg)
Credelio 450 mg pilloli li jintmagħdu għall-klieb (>11–22 kg)
Credelio 900 mg pilloli li jintmagħdu għall-klieb (>22–45 kg)
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
SUSTANZA ATTIVA:
Kull pillola li tintmagħad fiha:
CREDELIO PILLOLI LI JINTMAGĦDU GĦALL-KLIEB
LOTILANER (MG)
għall-klieb (1.3–2.5 kg)
56.25
għall-klieb (>2.5–5.5 kg)
112.5
għall-klieb (>5.5–11 kg)
225
għall-klieb (>11-22 kg)
450
għall-klieb (>22-45 kg)
900
SUSTANZI MHUX ATTIVI:
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola li tintmagħad.
Pilloli li jintmagħdu, tondi, ta’ lewn abjad sa kannella ċar,
b’tikek jagħtu fil-kannella.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Għall-kura ta’ infestazzjonijiet tal-briegħed u tal-qurdien
fil-klieb.
Dan il-prodott mediċinali veterinarju jipprovdi attività immedjata u
persistenti ta’ qtil għal xahar, għal
briegħed (
_Ctenocephalides felis _
u
_C. canis_
) u qurdien (
_Rhipicephalus sanguineus, Ixodes ricinus, I. _
_hexagonus u Dermacentor reticulatus_
).
Il-briegħed u l-qurdien iridu jeħlu mal-kelb (l-ospitu) u jibdew
jieklu (jixorbu d-demm) sabiex jiġu
esposti għas-sustanza attiva.
Il-prodott mediċinali veterinarju jista’ jintuża bħala parti minn
strateġija ta’ kura għall-kontroll ta’
dermatite minn allerġija minħabba l-briegħed (FAD,
_flea allergy dermatitis_
).
4.3
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ sensittività għall-ingredjent attiv;
ingredjenti mhux attivi jew ingredjenti oħra.
3
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA HU INDIKAT
IL-P
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-06-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-06-2021
Public Assessment Report Public Assessment Report Bulgarian 26-07-2018
Patient Information leaflet Patient Information leaflet Spanish 18-06-2021
Public Assessment Report Public Assessment Report Spanish 26-07-2018
Patient Information leaflet Patient Information leaflet Czech 18-06-2021
Public Assessment Report Public Assessment Report Czech 26-07-2018
Patient Information leaflet Patient Information leaflet Danish 18-06-2021
Public Assessment Report Public Assessment Report Danish 26-07-2018
Patient Information leaflet Patient Information leaflet German 18-06-2021
Public Assessment Report Public Assessment Report German 26-07-2018
Patient Information leaflet Patient Information leaflet Estonian 18-06-2021
Public Assessment Report Public Assessment Report Estonian 26-07-2018
Patient Information leaflet Patient Information leaflet Greek 18-06-2021
Public Assessment Report Public Assessment Report Greek 26-07-2018
Patient Information leaflet Patient Information leaflet English 18-06-2021
Public Assessment Report Public Assessment Report English 26-07-2018
Patient Information leaflet Patient Information leaflet French 18-06-2021
Public Assessment Report Public Assessment Report French 26-07-2018
Patient Information leaflet Patient Information leaflet Italian 18-06-2021
Public Assessment Report Public Assessment Report Italian 26-07-2018
Patient Information leaflet Patient Information leaflet Latvian 18-06-2021
Public Assessment Report Public Assessment Report Latvian 26-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 18-06-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-06-2021
Public Assessment Report Public Assessment Report Lithuanian 26-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 18-06-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 18-06-2021
Public Assessment Report Public Assessment Report Hungarian 26-07-2018
Patient Information leaflet Patient Information leaflet Dutch 18-06-2021
Public Assessment Report Public Assessment Report Dutch 26-07-2018
Patient Information leaflet Patient Information leaflet Polish 18-06-2021
Public Assessment Report Public Assessment Report Polish 26-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 18-06-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 18-06-2021
Public Assessment Report Public Assessment Report Portuguese 26-07-2018
Patient Information leaflet Patient Information leaflet Romanian 18-06-2021
Public Assessment Report Public Assessment Report Romanian 26-07-2018
Patient Information leaflet Patient Information leaflet Slovak 18-06-2021
Public Assessment Report Public Assessment Report Slovak 26-07-2018
Patient Information leaflet Patient Information leaflet Slovenian 18-06-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 18-06-2021
Public Assessment Report Public Assessment Report Slovenian 26-07-2018
Patient Information leaflet Patient Information leaflet Finnish 18-06-2021
Public Assessment Report Public Assessment Report Finnish 26-07-2018
Patient Information leaflet Patient Information leaflet Swedish 18-06-2021
Public Assessment Report Public Assessment Report Swedish 26-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 18-06-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 18-06-2021
Patient Information leaflet Patient Information leaflet Icelandic 18-06-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 18-06-2021
Patient Information leaflet Patient Information leaflet Croatian 18-06-2021
Public Assessment Report Public Assessment Report Croatian 26-07-2018

Search alerts related to this product

View documents history